Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Ref Type | |||||||||||||
PMID | |||||||||||||
Authors | Olivier Rixe, John Charles Morris, Vinay K. Puduvalli, John L. Villano, Trisha Michel Wise-Draper, Carolyn Muller, Angela N. Johnson, Robert Wesolowski, Xiaoyang Qi | ||||||||||||
Title | First-in-human, first-in-class phase 1a study of BXQ-350 for solid tumors and gliomas. | ||||||||||||
|
|||||||||||||
URL | http://ascopubs.org/doi/abs/10.1200/JCO.2018.36.15_suppl.2517 | ||||||||||||
Abstract Text | Journal of Clinical Oncology 36, no. 15_suppl (May 20 2018) 2517-2517 |
Molecular Profile | Treatment Approach |
---|
Gene Name | Source | Synonyms | Protein Domains | Gene Description | Gene Role |
---|
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
BXQ-350 | SapC-DOPS | SapC-DOPS (BXQ-350) is a nanovesicle of saposin C (SapC; a lysosomal protein) and dioleylphosphatidylserine (DOPS) that targets phosphatidylserine to activate lysosomes resulting in apoptosis in cells with high surface levels of phosphatidylserine (Journal of Clinical Oncology 36, no. 15_suppl (May 20 2018) 2517-2517, PMID: 31918715). |
Gene | Variant | Impact | Protein Effect | Variant Description | Associated with drug Resistance |
---|
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|